Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma.
- Author:
Won SOHN
1
;
Jonghwa KIM
;
So Hee KANG
;
Se Ra YANG
;
Ju Yeon CHO
;
Hyun Chin CHO
;
Sang Goon SHIM
;
Yong Han PAIK
Author Information
- Publication Type:Original Article
- MeSH: Adult; Aged; Biomarkers, Tumor/blood/genetics; Carcinoma, Hepatocellular/blood/diagnosis/*genetics; Exosomes/genetics; Female; Gene Expression Profiling; Humans; Liver/pathology; Liver Neoplasms/blood/diagnosis/*genetics; Male; MicroRNAs/blood/*genetics; Middle Aged
- From:Experimental & Molecular Medicine 2015;47(9):e184-
- CountryRepublic of Korea
- Language:English
- Abstract: Recent studies have shown that circulating microRNAs are a potential biomarker in various types of malignancies. The aim of this study was to investigate the feasibility of using serum exosomal microRNAs as novel serological biomarkers for hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We measured the serum exosomal microRNAs and serum circulating microRNAs in patients with CHB (n=20), liver cirrhosis (LC) (n=20) and HCC (n=20). Serum exosomal microRNA was extracted from 500 mul of serum using an Exosome RNA Isolation kit. The expression levels of microRNAs were quantified by real-time PCR. The expression levels of selected microRNAs were normalized to Caenorhabditis elegans microRNA (Cel-miR-39). The serum levels of exosomal miR-18a, miR-221, miR-222 and miR-224 were significantly higher in patients with HCC than those with CHB or LC (P<0.05). Further, the serum levels of exosomal miR-101, miR-106b, miR-122 and miR-195 were lower in patients with HCC than in patients with CHB (P=0.014, P<0.001, P<0.001 and P<0.001, respectively). There was no significant difference in the levels of miR-21 and miR-93 among the three groups. Additionally, the serum levels of circulating microRNAs showed a smaller difference between HCC and either CHB or LC. This study suggests that serum exosomal microRNAs may be used as novel serological biomarkers for HCC.
